Blood Test

WISDOM, a research study comparing annual mammography with a personalized approach to screening based on individual risk factors, is currently underway and enrolling women in the U.S. aged 30 to 74 years without a history of breast cancer.

A novel evaluation of biomarkers known to be associated with pancreatic cancer significantly improved detection of early-stage disease compared with previous tests, according to results of a double-blind phase 2 trial.

Both colonoscopies and stool-based tests for colorectal cancer screening may be more efficient and cost-effective compared with blood-based tests, study findings published in Annals of Internal Medicine showed.

Adults may soon have an easy way to know whether they face a heightened risk for COPD and death due to a respiratory disease with the creation of a preclinical blood test that assesses 32 proteins, according to a press release.

A blood test to measure fibrinogen-to-albumin ratio predicted preeclampsia and severe preeclampsia risk in laboring women compared with other blood markers, potentially providing a useful tool for anesthesiologists, researchers reported.

PHILADELPHIA — Patients with a false-positive Shield test result did not appear to be at increased risk for non-colorectal cancer malignancies at 1 year compared with those with a true-negative result, according to a presenter here.

A biomarker panel of three serum metabolites associated with the onset, severity and progression of age-related macular degeneration may aid in earlier detection and monitoring of disease, according to researchers.

A progressive neurodegenerative condition, ALS has no cure, with diagnosis often a result of protracted clinical evaluation that may take more than a year to accurately determine.

A simple blood test that measures lymphocyte count may accurately predict response to chimeric antigen receptor T-cell therapy among patients with relapsed multiple myeloma, according to study results.

C2N Diagnostics has been awarded more than $7 million from the Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator initiative to advance a novel platform intended to boost Alzheimer’s disease biomarker detection.